{"id":536974,"date":"2021-09-10T10:32:11","date_gmt":"2021-09-10T14:32:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/"},"modified":"2021-09-10T10:32:11","modified_gmt":"2021-09-10T14:32:11","slug":"synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/","title":{"rendered":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span>, <span class=\"xn-chron\">Sept. 10, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational\u00a0Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria\u00a0(HOX), during the\u00a0American Urological Association (AUA) Annual Meeting, being held virtually <span class=\"xn-chron\">September 10<\/span> \u2013 13<sup>th<\/sup>. <\/p>\n<p>Title:\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3286013-1&amp;h=848649094&amp;u=https%3A%2F%2Finvestor.synlogictx.com%2Fstatic-files%2F917dc048-1b6f-4ab8-b551-e1fc2521aeae&amp;a=Safety+and+Tolerability+of+an+Oxalate-Consuming+Synthetic+Biotic+Medicine%3A+SYNB8802+in+Healthy+Volunteers+with+Induced+Dietary+Hyperoxaluria\" rel=\"nofollow noopener\">Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary Hyperoxaluria<\/a><br \/>Abstract Number: 21-6087<\/p>\n<p>Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including:<\/p>\n<ul type=\"disc\">\n<li>SYNB8802 was generally well tolerated in healthy volunteers. There were no serious or systemic adverse events. The most frequent adverse events were mild or moderate, transient, and GI-related. <\/li>\n<li>Dietary Hyperoxaluria was successfully induced in healthy volunteers. <\/li>\n<li>Dose-responsive changes in urinary oxalate levels were observed with a significant reduction in urinary oxalate relative to placebo across three dose levels. <\/li>\n<li>A dose of 3e11 live cells administered three times daily with meals was selected as the dose for Part B of the study. <\/li>\n<ul type=\"circle\">\n<li>This dose was well-tolerated and resulted in a 28.6% (90% CI: -42.4 to -11.6) reduction from baseline urinary oxalate levels\u00a0compared to placebo.<\/li>\n<\/ul>\n<li>At the end of dosing, the mean 24-hour urinary oxalate level was 40.1 mg for subjects treated with SYNB8802 3e11 live cells, compared to 58.1 mg for placebo subjects. <\/li>\n<ul type=\"circle\">\n<li>Upper limit of normal urinary oxalate levels are 45 mg per 24 hours.<\/li>\n<\/ul>\n<\/ul>\n<p>Learn more about Synlogic&#8217;s programs and pipeline by visiting <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3286013-1&amp;h=139760557&amp;u=https%3A%2F%2Fwww.synlogictx.com%2F&amp;a=https%3A%2F%2Fwww.synlogictx.com%2F\" rel=\"nofollow noopener\">https:\/\/www.synlogictx.com\/<\/a>. <\/p>\n<p>\n        <b>About Enteric Hyperoxaluria<br \/><\/b>Enteric hyperoxaluria (HOX) is an acquired metabolic disorder caused by increased absorption of dietary oxalate, which is present in many common foods including leafy greens, nuts, and chocolate. Enteric hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, Crohn&#8217;s\u00a0disease,\u00a0short bowel syndrome,\u00a0or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery.<\/p>\n<p>Enteric hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis. There are an estimated 250,000 patients with enteric hyperoxaluria in <span class=\"xn-location\">the United States<\/span>. Enteric hyperoxaluria has no approved treatment options.\u00a0<\/p>\n<p>\n        <b>About SYNB8802<br \/><\/b>SYNB8802 is an engineered non-pathogenic strain of E. coli (Nissle), using Synlogic&#8217;s Synthetic Biotic platform, designed to consume oxalate in the GI tract and lower urinary oxalate levels, potentially reducing kidney damage due to enteric hyperoxaluria. SYNB8802 is administered orally. SYNB8802 is currently undergoing Phase 1 studies in healthy volunteers and patients with enteric hyperoxaluria. <\/p>\n<p>\n        <b>About Synlogic<br \/><\/b>Synlogic\u2122 is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic&#8217;s proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.<\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>This press release contains &#8220;forward-looking statements&#8221; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict&#8221; and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic&#8217;s platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism,\u00a0 and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic&#8217;s clinical trials and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of\u00a0Synlogic\u00a0to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading &#8220;Risk Factors&#8221; in\u00a0Synlogic&#8217;s\u00a0filings with the\u00a0SEC. The forward-looking statements contained in this press release reflect\u00a0Synlogic&#8217;s\u00a0current views with respect to future events.\u00a0Synlogic\u00a0anticipates that subsequent events and developments will cause its views to change. However, while\u00a0Synlogic\u00a0may elect to update these forward-looking statements in the future,\u00a0Synlogic\u00a0specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic&#8217;s view as of any date subsequent to the date hereof.<\/p>\n<p>\u00a0<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Media Contact:<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investor Contact:<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Daniel Rosan<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Synlogic, Inc.<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Phone: 617-207-5509<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Email: dan.rosan@synlogictx.com<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Daniel Rosan<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Synlogic, Inc.<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Phone: 617-207-5509<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Email: dan.rosan@synlogictx.com<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting-301373400.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting-301373400.html<\/a><\/p>\n<p>SOURCE  Synlogic, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE02205&amp;Transmission_Id=202109101029PR_NEWS_USPR_____NE02205&amp;DateId=20210910\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass., Sept. 10, 2021 \/PRNewswire\/ &#8212;\u00a0Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational\u00a0Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria\u00a0(HOX), during the\u00a0American Urological Association (AUA) Annual Meeting, being held virtually September 10 \u2013 13th. Title:\u00a0Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary HyperoxaluriaAbstract Number: 21-6087 Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including: SYNB8802 was generally well tolerated in healthy volunteers. There were no serious or systemic adverse events. The most frequent adverse events were mild or moderate, transient, and GI-related. Dietary Hyperoxaluria &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536974","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass., Sept. 10, 2021 \/PRNewswire\/ &#8212;\u00a0Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational\u00a0Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria\u00a0(HOX), during the\u00a0American Urological Association (AUA) Annual Meeting, being held virtually September 10 \u2013 13th. Title:\u00a0Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary HyperoxaluriaAbstract Number: 21-6087 Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including: SYNB8802 was generally well tolerated in healthy volunteers. There were no serious or systemic adverse events. The most frequent adverse events were mild or moderate, transient, and GI-related. Dietary Hyperoxaluria &hellip; Continue reading &quot;Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-10T14:32:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting\",\"datePublished\":\"2021-09-10T14:32:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/\"},\"wordCount\":853,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE02205&amp;sd=2021-09-10\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/\",\"name\":\"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE02205&amp;sd=2021-09-10\",\"datePublished\":\"2021-09-10T14:32:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE02205&amp;sd=2021-09-10\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE02205&amp;sd=2021-09-10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass., Sept. 10, 2021 \/PRNewswire\/ &#8212;\u00a0Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational\u00a0Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria\u00a0(HOX), during the\u00a0American Urological Association (AUA) Annual Meeting, being held virtually September 10 \u2013 13th. Title:\u00a0Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary HyperoxaluriaAbstract Number: 21-6087 Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including: SYNB8802 was generally well tolerated in healthy volunteers. There were no serious or systemic adverse events. The most frequent adverse events were mild or moderate, transient, and GI-related. Dietary Hyperoxaluria &hellip; Continue reading \"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-10T14:32:11+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting","datePublished":"2021-09-10T14:32:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/"},"wordCount":853,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/","name":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10","datePublished":"2021-09-10T14:32:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE02205&amp;sd=2021-09-10"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/synlogic-presents-data-on-synb8802-for-enteric-hyperoxaluria-at-american-urological-association-aua-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536974"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536974\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}